Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAG-524
- Development stage
- Preclinical
- Lead developer
- Kumamoto University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SAG-524 is an orally bioavailable, small-molecule hepatitis B virus (HBV) RNA destabilizer that acts by selectively inhibiting terminal nucleotidyltransferase 4B (TENT4B, also known as PAPD5). By inhibiting TENT4B, SAG-524 disrupts the protective polyadenylation (specifically guanine incorporation) of HBV RNA, leading to its rapid degradation and a subsequent reduction in the production of hepatitis B surface antigen (HBsAg), hepatitis B core-related antigen (HBcrAg), and HBV DNA. Developed by Kumamoto University, SAG-524 has demonstrated potent anti-HBV activity in vitro and in vivo, particularly when combined with nucleos(t)ide analogues or capsid assembly modulators, and has shown a favorable safety profile in preclinical animal models.
- Other names
- SAG524SAG-524SAG 524
02
Targets
TENT4B
Beyond the preview
Go deeper on SAG-524.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAG-524.